At the midpoint of the year, the global biopharma industry has recorded 554 partnering deals – a total that suggests that companies are still maintaining a high priority on business development through collaborations to help them execute on their business plans. The volume of partnering deals recorded by BioWorld in the second quarter, at 281, was about the same as those completed in the first quarter. However, year to date, the total number of transactions are about 10 percent down from the total recorded at this time last year. Read More
It was a positive and productive second quarter as far as biopharma's innovation engine was concerned. Following the six new molecular entities (NMEs) approved in the first quarter, the period saw 14 products receive the agency's green light. At the halfway point last year, 23 NMEs had been approved and the industry appears to be on pace, with the current 20 approvals, to test its recent high watermark for new drug approvals established last year at 46, a total that ranks as the second highest number of approvals all time, just behind 1996 when 53 new medicines were approved. Read More
